Daniela Barbero
Overview
Explore the profile of Daniela Barbero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zaccaria G, Ferrero S, Hoster E, Passera R, Evangelista A, Genuardi E, et al.
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008361
Background: Multicenter clinical trials are producing growing amounts of clinical data. Machine Learning (ML) might facilitate the discovery of novel tools for prognostication and disease-stratification. Taking advantage of a systematic...
2.
Impact of different exposure models and spatial resolution on the long-term effects of air pollution
Gariazzo C, Carlino G, Silibello C, Tinarelli G, Renzi M, Finardi S, et al.
Environ Res
. 2020 Nov;
192:110351.
PMID: 33130163
Long-term exposure to air pollution has been related to mortality in several epidemiological studies. The investigations have assessed exposure using various methods achieving different accuracy in predicting air pollutants concentrations....
3.
Della Starza I, De Novi L, Cavalli M, Novelli N, Soscia R, Genuardi E, et al.
Hematol Oncol
. 2020 Aug;
38(5):698-704.
PMID: 32816326
Minimal residual disease (MRD) assessment is of high clinical relevance in patients with mantle cell lymphoma (MCL). In mature B-cell malignancies, the presence of somatic hypermutations (SHM) in Variable-Diversity-Joining Heavy...
4.
Zaccaria G, Ferrero S, Rosati S, Ghislieri M, Genuardi E, Evangelista A, et al.
JCO Clin Cancer Inform
. 2019 Oct;
3:1-15.
PMID: 31633999
Purpose: Data collection in clinical trials is becoming complex, with a huge number of variables that need to be recorded, verified, and analyzed to effectively measure clinical outcomes. In this...
5.
Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund C, et al.
Haematologica
. 2019 Sep;
105(6):1604-1612.
PMID: 31537689
In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem cell transplantation. Nevertheless, a proportion of MCL patients...
6.
Della Starza I, Cavalli M, De Novi L, Genuardi E, Mantoan B, Drandi D, et al.
Hematol Oncol
. 2019 Jul;
37(4):368-374.
PMID: 31325190
In 2009, the four laboratories of the Fondazione Italiana Linfomi (FIL) minimal residual disease (MRD) Network started a collaborative effort to harmonize and standardize their methodologies at the national level,...
7.
Beccuti M, Genuardi E, Romano G, Monitillo L, Barbero D, Boccadoro M, et al.
BMC Bioinformatics
. 2017 Nov;
18(1):516.
PMID: 29169317
Background: Mantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. The most common molecular marker of clonality in MCL, as in...
8.
Ghione P, Genuardi E, Rossi D, Drandi D, Mantoan B, Barbero D, et al.
Br J Haematol
. 2017 Apr;
181(5):693-695.
PMID: 28369711
No abstract available.
9.
Visco C, Chiappella A, Nassi L, Patti C, Ferrero S, Barbero D, et al.
Lancet Haematol
. 2016 Dec;
4(1):e15-e23.
PMID: 27927586
Background: The combination of rituximab, bendamustine, and cytarabine (R-BAC) was highly active in a pilot trial of mantle cell lymphoma, but its use was restricted by high haematological toxicity. We...
10.
Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, et al.
J Mol Diagn
. 2015 Aug;
17(6):652-60.
PMID: 26319783
Real-time quantitative PCR (qPCR) is a well-established tool for minimal residual disease (MRD) detection in mature lymphoid malignancies. Despite remarkable sensitivity and specificity, qPCR has some limitations, particularly in the...